What is Leerink Partnrs’ Estimate for CRNX Q3 Earnings?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Research analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Crinetics Pharmaceuticals in a research report issued on Tuesday, February 4th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.14) for the quarter, down from their previous estimate of ($1.12). The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.24) EPS and FY2026 earnings at ($4.99) EPS.

Several other analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday, January 13th. Jefferies Financial Group raised shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, January 22nd. Citigroup upped their target price on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a “buy” rating in a report on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and set a $87.00 price target on shares of Crinetics Pharmaceuticals in a report on Monday, December 16th. Finally, Wolfe Research started coverage on Crinetics Pharmaceuticals in a research note on Tuesday. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.64.

Crinetics Pharmaceuticals Trading Down 4.5 %

Shares of NASDAQ:CRNX opened at $36.98 on Friday. The stock has a market cap of $3.43 billion, a PE ratio of -9.91 and a beta of 0.56. The stock’s fifty day simple moving average is $47.81 and its two-hundred day simple moving average is $51.89. Crinetics Pharmaceuticals has a 1-year low of $35.51 and a 1-year high of $62.53.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.05). During the same quarter in the prior year, the company posted ($1.01) earnings per share.

Institutional Trading of Crinetics Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in Crinetics Pharmaceuticals by 3.3% during the 2nd quarter. AQR Capital Management LLC now owns 7,126 shares of the company’s stock valued at $319,000 after buying an additional 227 shares in the last quarter. Creative Planning grew its stake in Crinetics Pharmaceuticals by 20.6% during the second quarter. Creative Planning now owns 12,997 shares of the company’s stock valued at $582,000 after acquiring an additional 2,224 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Crinetics Pharmaceuticals by 15.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 19,000 shares of the company’s stock worth $971,000 after acquiring an additional 2,600 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Crinetics Pharmaceuticals in the 3rd quarter worth approximately $91,000. Finally, Values First Advisors Inc. bought a new position in Crinetics Pharmaceuticals in the 3rd quarter valued at $84,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Insiders Place Their Bets

In other Crinetics Pharmaceuticals news, COO Jeff E. Knight sold 501 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.52, for a total transaction of $28,316.52. Following the sale, the chief operating officer now owns 51,653 shares of the company’s stock, valued at $2,919,427.56. The trade was a 0.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dana Pizzuti sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $39.07, for a total value of $195,350.00. Following the completion of the transaction, the insider now directly owns 31,748 shares of the company’s stock, valued at $1,240,394.36. The trade was a 13.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.